



# At a Glance


Olympus generates approximately 80% of its sales in the Medical Business, which primarily operates in the gastrointestinal endoscope field, where it holds a share of more than 70% of the global market. The Company's other businesses include the Scientific Solutions Business, which deals in microscopes and non-destructive testing equipment, and the Imaging Business, which sells digital cameras. These three businesses constitute the business domains of Olympus.




\* Figures above represent percentages of consolidated net sales of ¥804.6 billion in fiscal 2016.



## Share of Net Sales by Region (Consolidated)



## Share of Net Sales by Region (Medical)




## Medical Business

### Results of Operations in Fiscal 2016

In the Medical Business, performance was strong in the gastrointestinal endoscope field as well as in the surgical device and endotherapy device fields. Sales continued to increase for mainstay gastrointestinal endoscopes, as they did for surgical endoscopy systems and energy devices. By region, overall growth was driven by North America and Asia. As a result, net sales in the Medical Business increased 9% year on year, to ¥608.9 billion, and operating income rose 12%, to ¥140.2 billion.

### Net Sales



### Operating Income / Operating Margin




## Scientific Solutions Business


### Results of Operations in Fiscal 2016

The life science field operations saw sales of research-use equipment and other products decline due to delayed budget execution among research institutions. Sales of industrial field products, such as non-destructive testing equipment, also decreased, following the drop in resource prices. As a result, the Scientific Solutions Business posted a 2% year-on-year decrease in net sales, to ¥101.6 billion. Operating income, however, was up 24%, to ¥8.5 billion, reflecting reductions in cost of sales and increased efficiency through the integration of sales bases.

### Net Sales



### Operating Income / Operating Margin




## Imaging Business


### Results of Operations in Fiscal 2016

Although net sales declined 1% year on year, to ¥78.3 billion, in the Imaging Business, operating loss decreased from ¥11.7 billion in fiscal 2015 to ¥2.1 billion in fiscal 2016. This accomplishment was a result of our efforts to reduce the scale of this business and lower the level of expenses to match this scale while securing earnings and minimizing risks. We were unable to achieve our target of breaking even on the operating income level. Nonetheless, we did begin seeing the successes of our structural reforms, which included a substantial reduction in operating loss.

### Net Sales



### Operating Loss



(Note) The division of operations included in the Imaging Business was changed in fiscal 2015 and then again in fiscal 2016. Net sales figures for fiscal 2013 and fiscal 2014 use the division of operations after this change.

## Others

In Others, we provide bone replacement material and other biomaterials and also sell lens modules directly to other companies. In addition, this segment is responsible for seeking out new businesses and conducting R&D activities in relation to such businesses. To develop future pillars supporting the Company, we are searching for new business opportunities and advancing R&D and discovery activities for acquiring technologies.